Join us on Saturday, August 22^nd from 9:00 AM to 2:20 PM central time (10:00 AM to 3:20 PM eastern time). Breakfast and lunch buffets sponsored by AON.

• 9:00 AM – 9:05 AM — Introduction (Dr Divers)
• 9:05 AM – 9:55 AM — Module 1: Chronic Lymphocytic Leukemia (Dr Awan)
• 9:55 AM – 10:45 AM — Module 2: Gastroesophageal Cancers (Dr Klempner)
• 10:45 AM – 11:00 AM — Morning Break
• 11:00 AM – 11:50 AM — Module 3: Ovarian and Endometrial Cancer (Dr Westin)
• 11:50 AM – 12:40 PM — Lunch
• 12:40 PM – 1:30 PM — Module 4: Diffuse Large B-Cell Lymphoma (Dr LaCasce)
• 1:30 PM – 2:20 PM — Module 5: Lung Cancer (Dr Liu)
• 2:20 PM — Meeting adjourns

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Chronic Lymphocytic Leukemia (CLL)
Upon completion of this activity, participants should be able to

• Recognize the prognostic and clinical significance of various biomarkers (eg, del[17p], TP53 mutations, IGHV gene rearrangements) in chronic lymphocytic leukemia (CLL), and refine molecular testing algorithms for patients newly diagnosed with this disease. 
• Individualize the selection of systemic therapy for newly diagnosed CLL, considering risk profile, clinical presentation, coexisting medical conditions and patient preferences. 
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents. 
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options. 
• Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line therapy for CLL to effectively inform patients about the risks and benefits of this novel treatment strategy.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data with this strategy for patients with newly diagnosed and relapsed/refractory (R/R) CLL. 
• Appraise clinical investigator best practices for various R/R CLL management scenarios, and leverage this information to facilitate improved therapeutic decision-making. 
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and as applicable, discuss clinical trial participation with eligible patients. 

Gastroesophageal Cancers
Upon completion of this activity, participants should be able to 

• Review published research findings with HER2-targeted therapies for patients with newly diagnosed and R/R advanced HER2-positive gastroesophageal cancers, and assess the current role of various agents and regimens. 
• Describe the published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms. 
• Evaluate the biological rationale for the use of claudin 18.2 (CLDN18.2)-directed monoclonal antibody therapy in combination with chemotherapy as first-line treatment for HER2-negative, CLDN18.2-positive gastric or GEJ cancer, and optimally deploy this approach in patient care. 
• Recognize available clinical research findings with immune checkpoint inhibitors as neoadjuvant, adjuvant or perioperative therapy for patients with resectable gastric, GEJ and esophageal cancers, and consider the current role of these approaches. 
• Review the rationale for, available data with and ongoing studies evaluating novel agents and strategies for gastroesophageal cancers in order to prepare for potential clinical availability or to enhance clinical trial participation. 

Ovarian and Endometrial Cancer
Upon completion of this activity, participants should be able to 

• Recognize the rationale for targeting folate receptor alpha (FRα) in ovarian cancer (OC), and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates (ADCs). 
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the role of this novel therapeutic strategy. 
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and integrate this novel approach into current management algorithms. 
• Assess the incidence of cadherin-6 expression in OC, and understand available data with and the structural components and mechanism of action of novel ADCs directed at this target. 
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate this novel strategy into the care of patients with microsatellite instability-high/mismatch repair (MMR)-deficient and microsatellite-stable/MMR-proficient disease. 
• Evaluate published clinical research documenting the efficacy of HER2-targeted agents and regimens for HER2-overexpressing gynecologic cancers, and consider the role of various approaches in patient care. 
• Recognize the biological rationale for the evaluation of trophoblast cell surface antigen 2 (TROP2)-directed ADCs for patients with gynecologic cancers, and consider available and emerging research findings with and the clinical potential of these agents. 
• Describe the scientific justification for, published data with and current research studies of novel agents and strategies for OC and EC, and effectively prioritize clinical trial opportunities for eligible patients. 

Diffuse Large B-Cell Lymphoma (DLBCL)
Upon completion of this activity, participants should be able to

• Identify patients with newly diagnosed and R/R diffuse large B-cell lymphoma (DLBCL) for whom CD79b-targeted therapy would be appropriate. 
• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies for newly diagnosed and R/R DLBCL, and consider the current and future role of this therapeutic strategy. 
• Appraise the biological rationale for, available research findings with and current clinical role of CD19-targeted ADCs for R/R DLBCL. 
• Evaluate available clinical trial findings and ongoing research studies with BTK inhibitors for DLBCL. 
• Develop an understanding of the biological rationale for the development of CD19-directed chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells in patients with DLBCL. 
• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for various forms of DLBCL, and assess the similarities and differences among currently available agents in this class. 
• Evaluate the available clinical research database with CD19-directed CAR T-cell therapy and CD20 x CD3 bispecific antibodies for the management of R/R DLBCL, and optimally incorporate these approaches into current treatment algorithms. 
• Assess available research findings with CD19-directed bispecific antibodies for DLBCL, and consider the potential role of these agents in therapy for patients with this disease. 
• Recall new data with agents and strategies currently under investigation for DLBCL, and discuss ongoing trial opportunities with eligible patients. 

Lung Cancer
Upon completion of this activity, participants should be able to

• Appreciate the incidence of HER2 mutations and overexpression in metastatic non-small cell lung cancer (NSCLC), and recognize published clinical trial data with and the current role of novel ADCs for HER2-positive disease. 
• Review available clinical trial data evaluating the efficacy and safety of HER2-targeted tyrosine kinase inhibitors for patients with HER2-mutant NSCLC, and optimally identify individuals appropriate for this novel therapeutic strategy. 
• Convey the clinical relevance of a positive ROS1 mutation testing result to appropriate patients with NSCLC, and appreciate available clinical research findings with recently approved and emerging agents demonstrating efficacy for these individuals. 
• Appreciate the biological rationale for the evaluation of TROP2-directed ADCs for various lung cancer patient populations, and identify individuals appropriate for therapy with FDA-approved and investigational agents. 
• Understand the biology of EGFR exon 20 insertion mutations, and evaluate how currently available and emerging therapies can be employed in the care of patients with NSCLC harboring these abnormalities. 
• Reflect on investigational agents and strategies currently in testing for lung cancer in preparation for the potential clinical availability of these approaches. 

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 4.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 4.25 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statement
This educational activity for 4.25 contact hours is provided by Research To Practice.

This activity is awarded 4.25 ANCC pharmacotherapeutic contact hours.

ONCC/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/AON2026/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Professional Development provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.0425 CEU (4.25 contact hours) of continuing education credit. To receive 4.25 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc. Dr Klempner — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, BeOne, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, EsoBiotec, Gilead Sciences Inc, I-Mab Biopharma, Jazz Pharmaceuticals Inc, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Signet Therapeutics, Taiho Oncology Inc; Consulting Agreements: Astellas; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, I-Mab Biopharma, Mersana Therapeutics Inc, Parabilis Medicines; Data and Safety Monitoring Boards/Committees: Sanofi; Stock OPTIONS — Private Companies: MBrace Therapeutics; Nonrelevant Financial Relationships: Debbie’s Dream Foundation, Degregorio Family Foundation, Gastric Cancer Foundation, National Cancer Institute/National Institutes of Health, NCCN (member of Gastric and Esophageal Guidelines Committees), Stand Up 2 Cancer/AACR, Torrey Coast Foundation. Dr LaCasce — Advisory Committees: Caribou Biosciences Inc, Genmab US Inc, Kite, A Gilead Company; Consulting Agreements: Genmab US Inc, Pierre Fabre, Takeda Pharmaceuticals USA Inc. Dr Liu — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Jazz Pharmaceuticals Inc, Johnson & Johnson, Merck, Merus, Natera, Novartis, Nuvalent, OSE Immunotherapeutics, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, SystImmune Inc, Takeda Pharmaceuticals USA Inc, Yuhan Corporation; Contracted Research: AbbVie Inc, Alkermes, Amgen Inc, AstraZeneca Pharmaceuticals LP, Avenzo Therapeutics, BioNTech SE, Cogent Biosciences, Duality Biologics, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Henlius, MediLink Therapeutics, Merck, Merus, Nuvalent, Nuvation Bio Inc, OSE Immunotherapeutics, Puma Biotechnology Inc, Synthekine, SystImmune Inc. Dr Westin — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Faeth Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, Immunocore, ImmunoGen Inc, Incyte Corporation, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mereo BioPharma, NGM Biopharmaceuticals, Nuvectis Pharma Inc, Ottimo Pharma, Pfizer Inc, pharmaand GmbH, PMV Pharma, Seagen Inc, Verastem Inc, Zentalis Pharmaceuticals, ZielBio; Contracted Research: AstraZeneca Pharmaceuticals LP, Avenge Bio, Bayer HealthCare Pharmaceuticals, Bio-Path Holdings Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, GSK, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mereo BioPharma, Novartis, Nuvectis Pharma Inc, Pfizer Inc, pharmaand GmbH, Verastem Inc, Zentalis Pharmaceuticals.

MODERATOR
Dr Divers — Advisory Committees: Daiichi Sankyo Inc.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP,  BeOne, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Genmab US Inc, Jazz Pharmaceuticals Inc, and Lilly.

JW Marriott Nashville
201 8th Avenue South
Nashville, TN 37203
Hotel Phone: (615) 291-8600

Meeting Room
Griffin A, B, C, D (second floor)

Hotel Room Reservations

• American Oncology Network (AON) members, please be sure to book accommodations in the AON room block.
• For all other registrants, room reservation information will be included in the confirmation email after you have registered for this program.

MODULES 1, 2 AND 3: Chronic Lymphocytic Leukemia, Gastroesophageal Cancers and Ovarian and Endometrial Cancers

• Slide Presentations (PDF)
• Slide Presentations (PPT)

MODULES 4 AND 5: Diffuse Large B-Cell Lymphoma and Lung Cancer

• Slide Presentations (PDF)
• Slide Presentations (PPT)

This event has passed.

Thank you for your interest in our CME/MOC, ACPE and NCPD program. At this time online registration for in-person attendance is closed for this event. 

Our onsite registration desk will be open at 8:30 AM central time on Saturday, August 22nd. If you are interested in attending, please visit our registration desk in the foyer of Griffin Ballroom A-D on the second floor of the JW Marriott Nashville hotel. Please note, seating is limited for this event, and we will do our best to accommodate onsite registrants on a first come, first served basis but prioritizing clinicians in practice. Onsite registration does not guarantee participation in meal services.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

Faculty

Faculty

Blanca Ledezma

MSN, NP, AOCNP

Department of Hematology Oncology Santa Monica, California

UCLA Health

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Heather McArthur

MD, MPH, FASCO

UT Southwestern Medical Center, Dallas, Texas

Professor, Department of Internal Medicine, Clinical Director, Breast Cancer Program, Komen Distinguished Chair in Clinical Breast Cancer Research

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology and Current Management of Hormone-Receptor (HR)-Positive Metastatic Breast Cancer (mBC); Clinical Relevance of ESR1 Mutations

• Incidence, pathophysiology and clinical characteristics of HR-positive mBC
• Current role of endocrine-based therapies in the management of HR-positive mBC; known mechanisms of resistance to hormonal therapy
• Prevalence of ESR1 mutations in HR-positive, HER2-negative mBC; relevance of prior therapeutic exposure
• Optimal timing and approach to testing for ESR1 mutations in patients with HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating assessment for ESR1 status in patients with HR-positive, HER2-negative mBC and in helping them understand the implications of results

MODULE 2: Current Role of Oral Selective Estrogen Receptor Degraders (SERDs) in Therapy for HR-Positive mBC

• Mechanistic similarities and differences between fulvestrant and the various available and investigational oral SERDs; implications for efficacy and tolerability
• Published efficacy outcomes with elacestrant for patients with progressive HR-positive, HER2-negative mBC
• Major findings documenting the efficacy of imlunestrant monotherapy for patients with pretreated HR-positive, HER2-negative mBC
• FDA approvals of elacestrant and imlunestrant for patients with previously treated HR-positive, HER2-negative mBC and ESR1 mutations
• Identification of patients appropriate for treatment with elacestrant or imlunestrant

MODULE 3: Potential Role of Early Therapeutic Switching from an Aromatase Inhibitor to an Oral SERD After Detection of an Emergent ESR1 Mutation During First-Line Therapy for HR-Positive mBC

• Early-phase data with camizestrant alone for previously treated HR-positive, HER2-negative advanced breast cancer
• Biological rationale for and potential benefit of serial ESR1 testing for patients receiving first-line endocrine therapy
• Design, eligibility criteria and key efficacy and safety findings from the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
• Potential role of serial ESR1 testing and early therapeutic switching for patients found to harbor ESR1 mutations

MODULE 4: Potential Role of Combination Approaches with Oral SERDs for HR-Positive, HER2-Negative Breast Cancer

• Biological rationale for combining oral SERDs with other systemic therapies, such as CDK4/6 inhibitors or PI3K/AKT/mTOR inhibitors
• Efficacy and safety outcomes documented with imlunestrant/abemaciclib for patients with HR-positive, HER2-negative advanced breast cancer with and without ESR1 mutations
• Recently presented data comparing giredestrant in combination with everolimus to standard endocrine therapy with everolimus for pretreated HR-positive, HER2-negative mBC
• Potential role of oral SERD-containing combination regimens and identification of patients appropriate for this approach
• Ongoing assessments of other oral SERD-based strategies for patients with HR-positive breast cancer

MODULE 5: Tolerability of Currently Approved and Investigational Oral SERDs

• Spectrum, frequency and severity of common class-effect toxicities, such as gastrointestinal (GI) side effects, musculoskeletal pain, fatigue and myelosuppression, documented with oral SERDs; comparative tolerability of elacestrant and imlunestrant
• Recommended prophylaxis, monitoring and management of GI toxicities associated with oral SERDs
• Pathophysiology of hyperlipidemia observed with elacestrant and imlunestrant; optimal lipid-profile monitoring for patients receiving either agent
• Incidence and severity of anemia and hypocalcemia noted with imlunestrant versus other oral SERDs; appropriate monitoring for and management of laboratory-value abnormalities in patients receiving these agents

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
• Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
• Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with hormone receptor (HR)-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
• Review available research findings with serial ESR1 testing using ctDNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
• Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
• Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.
• Assess ongoing clinical research evaluating novel applications of oral SERDs for HR-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OralSERDsMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Ledezma — Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Pfizer Inc; Steering Committees: AstraZeneca Pharmaceuticals LP. Dr Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc.

MODERATOR — Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Kelly Fischer

MSN, FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Family Nurse Practitioner

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Rita Nanda

MD

The University of Chicago, Chicago, Illinois

Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

MODULE 1: Appropriate Risk Assessment for Patients with Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer; Rationale for the Use of CDK4/6 Inhibitors for Those at High Risk for Recurrence

• Clinicopathologic factors (eg, age, tumor size and grade, nodal involvement) affecting the risk of recurrence for patients with HR-positive, HER2-negative localized breast cancer
• Long-term outcomes achieved with standard adjuvant endocrine therapy with or without chemotherapy for patients with HR-positive, HER2-negative localized breast cancer, including those at high risk for recurrence
• Mechanism of antitumor activity of CDK4/6 inhibitors; similarities and differences among available agents in this class
• Rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer

MODULE 2: Role of Adjuvant CDK4/6 Inhibitor Therapy for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer

• Extended follow-up, including recently published overall survival outcomes, with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
• Five-year outcomes with ribociclib and endocrine therapy compared to endocrine therapy alone as adjuvant treatment for high-risk, HR-positive, HER2-negative localized breast cancer
• FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib

MODULE 3: CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC)

• Long-term follow-up data with abemaciclib, palbociclib and ribociclib for patients with HR-positive mBC
• Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for premenopausal and postmenopausal patients
• Role of CDK4/6 inhibitors in treatment for unique patient populations, such as those with aggressive visceral disease and those with CNS metastases
• Available data on the utility of continuing CDK4/6 inhibitors beyond progression or rechallenge in later lines of therapy; current role of this strategy in clinical practice

MODULE 4: Cytopenias Associated with CDK4/6 Inhibitors

• Similarities and differences in the tolerability profiles of abemaciclib, palbociclib and ribociclib; spectrum and frequency of commonly occurring class-effect toxicities, such as cytopenias, gastrointestinal (GI) events and fatigue
• Appropriate monitoring of complete blood counts during CDK4/6 inhibitor therapy
• Thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias on CDK4/6 inhibitor therapy

MODULE 5: GI Adverse Events Documented with CDK4/6 Inhibitors

• Rates of various GI issues (eg, diarrhea, nausea and vomiting, constipation, abdominal pain) in patients receiving CDK4/6 inhibitor therapy
• Indications for antidiarrheals and/or antiemetics for patients receiving CDK4/6 inhibitors
• Role of nutritional counselling and diet modifications in CDK4/6 inhibitor treatment

MODULE 6: Rarer but Potentially Serious Toxicities Associated with 1 or More CDK4/6 Inhibitors

• Incidence of interstitial lung disease/pneumonitis associated with CDK4/6 inhibitor therapy; recommended algorithms for monitoring, mitigation and management
• Frequency and severity of hepatotoxicity documented with CDK4/6 inhibitors; appropriate monitoring of liver function tests before and during treatment
• Rates of venous thromboembolic events (VTE) reported with CDK4/6 inhibitor therapy; optimal monitoring for signs of VTE and precautionary measures for patients with preexisting risk factors
• Severe cutaneous adverse reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms) documented with CDK4/6 inhibitors; role of dermatologic consultation in the care of patients with signs or symptoms
• Incidence of cardiac toxicity with ribociclib; appropriate use of electrocardiogram monitoring before and during therapy

MODULE 7: Practical Considerations with CDK4/6 Inhibitors

• Optimal dosing and dose-adjustment strategies with CDK4/6 inhibitors for patients with localized and metastatic breast cancer
• Recommended duration of CDK4/6 inhibitor therapy in the adjuvant setting
• Approaches for encouraging and assessing adherence for patients receiving CDK4/6 inhibitor therapy
• Drug-drug interactions noted with 1 or more CDK4/6 inhibitors

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of hormone receptor (HR)-positive disease.
• Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
• Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
• Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
• Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
• Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATOR — Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Lilly and Novartis.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Beth Faiman

PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Adult Nurse Practitioner, Department of Hematology and Medical Oncology

Case Comprehensive Cancer Center, Cleveland, Ohio

Member, Population and Cancer Prevention Program

Faculty

Hans Lee

MD

Sarah Cannon Research Institute, Nashville, Tennessee

Director, Multiple Myeloma Research

Faculty

Mary Steinbach

PhD-c, DNP, FNP-C, APRN

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

Lead Ambulatory Advanced Practice Clinician, Division of Hematology

Moderator

Natalie S Callander

MD

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Rationale for targeting B-cell maturation antigen (BCMA) with CAR T-cell therapy for MM
• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for heavily pretreated MM
• Available data with and FDA approvals of ide-cel and cilta-cel in earlier settings; overall survival (OS) advantage documented with cilta-cel
• Identification of appropriate candidates for BCMA-targeted CAR T-cell therapy and optimal sequencing of this strategy opposite other evidence-based approaches
• Early data with and ongoing evaluation of CAR T-cell platforms with targets beyond BCMA (eg, the GPRC5D-directed agent arlocabtagene autoleucel)

MODULE 2: Tolerability and Other Practical Considerations with CAR T-Cell Therapy

• Overview of the CAR T-cell manufacturing and delivery processes
• Incidence, timing and signs and symptoms of cytokine release syndrome (CRS), neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) and other acute adverse events (AEs) with CAR T-cell therapy; optimal patient monitoring after infusion
• Guideline-endorsed approaches for mitigation and management of CRS, neurotoxicity/ICANS and other AEs with CAR T-cell therapy; role of corticosteroids, tocilizumab and other supportive care interventions
• Educating patients about practical requirements after CAR T-cell infusion (eg, the need to remain within proximity of the treatment center, recommendations regarding driving); implications of the recent elimination of the Risk Evaluation and Mitigation Strategy program for CAR T-cell therapy
• Potential for long-term tolerability/toxicity concerns (eg, delayed neurotoxicity, prolonged cytopenias, hypogammaglobulinemia, infections, secondary malignancies) with CAR T-cell therapy

MODULE 3: Role of B-Cell Maturation Antigen (BCMA)- and Non-BCMA-Targeted Bispecific Antibodies for MM

• Mechanistic similarities and differences between bispecific antibodies and CAR T-cell therapy; targets of various approved bispecific antibodies (eg, teclistamab, elranatamab, linvoseltamab, talquetamab)
• Long-term outcomes observed in pivotal trials of the BCMA-targeted bispecific antibodies teclistamab and elranatamab for heavily pretreated MM
• Efficacy and safety data leading to the FDA approval of the anti-BCMA bispecific antibody linvoseltamab for R/R MM
• Available efficacy and safety data with the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease
• Optimal selection of candidates with R/R MM for BCMA- and non-BCMA-targeted bispecific antibodies; considerations guiding the sequencing of these agents relative to other strategies and each other

MODULE 4: Toxicities and Practical Issues Related to Bispecific Antibodies

• Potential practical advantages of the “off-the-shelf” nature of bispecific antibodies
• Routes of administration, recommended dosing schedules and premedications with the various bispecific antibody platforms for MM; duration of hospitalization during step-up dosing
• Comparative tolerability of BCMA- and non-BCMA-directed bispecific antibodies for MM
• Incidence, severity and time course of CRS and neurotoxicity with bispecific antibodies; recommended protocols for mitigation and management
• Spectrum, frequency and management of other toxicities (eg, hepatotoxicity, infections, neutropenia, skin- and nail-related AEs, oral toxicities) reported with one or more bispecific antibodies

MODULE 5: Utility of Belantamab Mafodotin for R/R MM

• Mechanism of action and structural components of the BCMA-directed antibody-drug conjugate belantamab mafodotin
• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM; rationale for the withdrawal of this agent
• Key findings with belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone for patients who have received ≥1 prior line of therapy; OS advantage documented with the former combination
• Ongoing FDA review of belantamab mafodotin-based combination strategies; potential clinical role for R/R MM

MODULE 6: Tolerability Considerations with Belantamab Mafodotin

• Pathophysiology and symptomatology of the ocular AEs observed with belantamab mafodotin; impact of dosing on frequency and severity of ocular AEs
• Indications for and timing of ophthalmologic referral for patients about to receive belantamab mafodotin
• Optimal approaches to the management of ocular toxicities with belantamab mafodotin
• Spectrum, frequency, severity and management of other common and uncommon toxicities reported with belantamab mafodotin

MODULE 7: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) for MM

• Mechanism of action of the CELMoDs iberdomide and mezigdomide; similarities and differences between CELMoDs and standard immunomodulatory agents (IMiDs)
• Published efficacy and safety findings with iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for pretreated MM
• Rationale for the use of minimal residual disease (MRD) negativity as a clinical trial endpoint for MM; emerging Phase III data indicating an improvement in MRD negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs

MODULE 8: Tolerability/Toxicity Considerations with CELMoDs for MM

• Comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs
• Spectrum, frequency and severity of hematologic AEs observed with CELMoDs in published clinical studies
• Incidence and time course of nonhematologic complications (eg, gastrointestinal toxicities, cutaneous AEs, fatigue, infections, peripheral neuropathy) reported with CELMoDs
• Toxicity and tolerability of iberdomide and mezigdomide in combination with other effective antimyeloma therapies; strategies to discern the effects of each individual agent
• Appropriate monitoring, mitigation and management protocols for hematologic and nonhematologic side effects with CELMoDs

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
• Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
• Educate patients with R/R MM about the mechanism of action of, available data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
• Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential clinical role of this form of treatment.
• Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
• Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Faiman — Advisory Committees and Consulting Agreements: Janssen Biotech Inc, Sanofi. Dr Lee — Consulting Agreements (Paid to Institution): AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements (Paid to Self): Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc. Dr Steinbach — Advisory Committees: Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research and Speakers Bureaus: Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Callander has no relevant financial relationships to disclose.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Farrukh T Awan

MD

University of Texas Southwestern Medical Center, Dallas, Texas

Professor of Internal Medicine, Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies, Director of Lymphoid Malignancies Program, Harold C Simmons Comprehensive Cancer Center

Faculty

Robin Klebig

MSN, APRN, CNP, AOCNP

Mayo Clinic, Rochester, Minnesota

Hematology Outpatient APP Supervisor, Assistant Professor of Medicine, Nurse Practitioner, Lymphoma Group, Division of Hematology

Faculty

Mollie Moran

APRN-CNP, AOCNP

The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio

Nurse Practitioner

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting

MODULE 1: Current Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma (NHL)

• Design of bispecific antibodies to engage 2 disease targets with 1 molecule; potential therapeutic advantages over traditional monoclonal antibodies
• Scientific rationale for the selection of CD20 and CD3 as targets for bispecific antibodies in NHL; mechanism of antitumor activity
• Pharmacological similarities and differences among the various approved (eg, glofitamab, epcoritamab, mosunetuzumab) and investigational (eg, odronextamab) CD20 x CD3 bispecific antibodies for NHL; implications for efficacy, tolerability and ease of use
• Similarities and differences between bispecific antibodies and chimeric antigen receptor T-cell therapy
• FDA-approved indications for mosunetuzumab, glofitamab and epcoritamab; optimal selection and sequencing of bispecific antibodies for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

MODULE 2: Tolerability Concerns with Bispecific Antibodies for NHL

• Pathophysiology of the CRS and neurotoxicity observed with bispecific antibody therapy, including immune effector cell-associated neurotoxicity syndrome (ICANS)
• Comparative incidence and severity of CRS with bispecific antibodies available for various NHL subtypes
• Common signs and symptoms and typical course of CRS
• Clinical presentation of neurotoxicity/ICANS and common symptoms, such as delirium, dysphasia, lethargy, difficulty concentrating and confusion
• Guideline-endorsed approaches for monitoring, mitigation and management of CRS and neurotoxicity; role of corticosteroids, tocilizumab and other supportive care interventions
• Spectrum, frequency and severity of other common tolerability concerns, such as cytopenia, infections, fatigue, rash, musculoskeletal pain and gastrointestinal (GI) adverse events (AEs), with bispecific antibodies for patients with NHL

MODULE 3: Role of Polatuzumab Vedotin in Therapy for DLBCL

• Structural components of polatuzumab vedotin and mechanism of antitumor activity
• Extended follow-up with polatuzumab vedotin/R-CHP (rituximab, cyclophosphamide, doxorubicin and prednisone) for previously untreated DLBCL
• Current role of polatuzumab vedotin as a component of up-front therapy for DLBCL; appropriate selection of candidates for this strategy
• Efficacy and safety findings with polatuzumab vedotin in combination with chemoimmunotherapy (bendamustine/rituximab, rituximab/gemcitabine/oxaliplatin) or bispecific antibodies (mosunetuzumab) for patients with relapsed/refractory (R/R) DLBCL; current and potential role of these regimens

MODULE 4: Tolerability Considerations with Polatuzumab Vedotin

• Rates and severity of peripheral neuropathy with polatuzumab vedotin; appropriate use of dose adjustments and other management strategies
• Incidence of cytopenias and infections with polatuzumab vedotin-containing regimens; appropriate monitoring of complete blood counts (CBCs) during therapy
• Spectrum and incidence of GI AEs with polatuzumab vedotin-based therapy; strategies for management
• Differences, if any, in the tolerability of polatuzumab vedotin in the up-front versus the R/R setting; implications for AE monitoring and management

MODULE 5: Optimal Application of Loncastuximab Tesirine for Patients with DLBCL or FL

• Mechanism of action and structural makeup of the anti-CD19 antibody-drug conjugate loncastuximab tesirine
• Long-term findings with loncastuximab tesirine for R/R DLBCL; patient selection and optimal sequencing
• Available data with loncastuximab tesirine in combination with other therapies and for other NHL subtypes
• Recent NCCN guideline inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 6: Tolerability Considerations with Loncastuximab Tesirine

• Incidence, severity and management of edema and effusions with loncastuximab tesirine
• Rates of myelosuppression and infections with loncastuximab tesirine; appropriate monitoring of CBCs during therapy
• Spectrum of cutaneous reactions documented with loncastuximab tesirine, such as photosensitivity reactions, rash and erythema; recommended strategies for mitigation and management
• Initial dosing and dose-modification strategies with loncastuximab tesirine; recommended premedications, such as dexamethasone and G-CSF, for some or all patients

MODULE 7: Current and Future Role of Covalent and Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitors in the Management of Chronic Lymphocytic Leukemia (CLL)

• Indications for initiating active therapy for patients with previously untreated CLL
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for patients with treatment-naïve and R/R CLL; application in current up-front decision-making
• Comparative antitumor activity of BTK inhibitors alone and in combination with anti-CD20 antibodies in the up-front setting; implications for therapy selection

MODULE 8: Tolerability of Covalent and Noncovalent BTK Inhibitors

• Incidence and severity of cardiac arrhythmias, including atrial fibrillation or flutter, documented with approved covalent BTK inhibitors
• Probability of other cardiovascular toxicities, such as stroke, hypertension and bruising or bleeding events, with covalent BTK inhibitor therapy
• Spectrum and frequency of clinically relevant noncardiovascular toxicities, including cytopenias, infections, headache, dermatologic symptoms, arthralgia/myalgia and GI events, with covalent BTK inhibitors
• Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving covalent BTK inhibitors
• Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
• Incidence and severity of cardiac arrhythmias and other cardiovascular and noncardiovascular toxicities documented with pirtobrutinib
• Appropriate monitoring for and management of treatment-related AEs in patients receiving pirtobrutinib
• Safety profile of pirtobrutinib in the front-line setting

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate available research findings with CD20 x CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and counsel patients regarding the risks and benefits of this novel approach.
• Recognize the spectrum, frequency and severity of adverse events, such as cytokine release syndrome, neurotoxicity, infections and cytopenias, associated with CD20 x CD3 bispecific antibodies, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Identify patients with newly diagnosed and R/R DLBCL for whom CD79b-targeted antibody-drug conjugate (ADC) therapy would be appropriate.
• Appraise available research findings with and the current clinical role of CD19-targeted ADCs for patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with ADCs commonly used in the care of patients with NHL.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and R/R CLL, and identify patients appropriate for treatment with these agents.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review data with and the current and potential role of this strategy for patients with newly diagnosed and R/R CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with BTK inhibitors in the management of CLL.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/NHLandCLL/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Klebig and Ms Moran have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc.

MODERATOR — Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Lilly.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.